commercial or financial information which . . . is privileged or confidential''—as provided by Section 6(f) of the FTC Act, 15 U.S.C. 46(f), and FTC Rule 4.10(a)(2), 16 CFR 4.10(a)(2)—including in particular competitively sensitive information such as costs, sales statistics, inventories, formulas, patterns, devices, manufacturing processes, or customer names.

Josephine Liu,

Assistant General Counsel for Legal Counsel.

[FR Doc. 2026–16827 Filed 8–17–26; 8:45 am]

BILLING CODE 6750–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[Office of Management and Budget #: 0970–0430]

Submission for Office of Management and Budget Review; ACF–700 Tribal Annual Report

AGENCY: Office of Child Care, Administration for Children and Families, Department of Health and Human Services.

ACTION: Request for public comments.

SUMMARY: The Administration for Children and Families (ACF) is requesting to reinstate approval of the ACF–700: Tribal Annual Report (Office of Management and Budget (OMB) #: 0970–0430) with proposed revisions. ACF requests changes to the form that reduce annual burden hours.

DATES: Comments due September 17, 2026.

ADDRESSES: The public may view and comment on this information collection request at: *https://www.reginfo.gov/public/do/PRAViewICR?ref_nbr=202608-0970-005.* You can also obtain copies of the proposed collection of information by emailing *infocollection@acf.hhs.gov.* Identify all emailed requests by the title of the information collection.

SUPPLEMENTARY INFORMATION:

Description: Tribal Lead Agencies (TLA) for the Child Care and Development Fund (CCDF) are required on an annual basis to submit aggregate information on services provided via ACF–700 CCDF Tribal Annual Report. This report offers the Office of Child Care (OCC) insight into how CCDF program dollars are being spent. The ACF–700 report collects administrative data about the number of children and families served. The report also asks specific questions that collect programmatic information about tribal quality activities, coordination of activities with other early childhood programs, compliance with health and safety standards, and pursuit of accreditation. The information collected from this report allows OCC to generate and analyze aggregate information, thereby giving OCC a more comprehensive understanding of tribal program activities more easily. The data are essential for demonstrating the accomplishments of tribal child care programs. OCC has revised the previous version of the ACF–700 to reduce administrative burden for tribes. Specifically:

Part 2: Tribal Narrative on the form was reduced due to repetitive questions.

Part 3: American Rescue Plan (ARP) was deleted since OCC is no longer collecting ARP data.

Respondents: Tribal Grantees receiving CCDF funding. Tribes that operate child care under Public Law 102–477 Indian Employment, Training, and Related Services Plan are exempt from ACF–700.

Annual Burden Estimates: OCC has revised burden estimates based on the proposed revisions and to reflect the current number of TLAs. In prior years, burden was broken out by the size of the TLA, with small allocation tribes estimated to take less time to complete the request than medium/large allocation tribes. OCC is no longer differentiating between TLAs with small and medium/large allocations because most TLAs (74 percent) receive small allocations. Due to this and based on the revisions, OCC estimates an average time per response for all TLAs, regardless of size, of 13 hours. Overall, the proposed revisions result in a 40 percent decrease in burden compared to the currently approved information collection.

Instrument	Total number of respondents	Annual number of responses per respondent	Average burden hours per response	Annual burden hours
ACF–700	210	1	13	2,730

Authority: 42 U.S.C. 9857, *et seq.*

Mary C. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2026–16793 Filed 8–17–26; 8:45 am]

BILLING CODE 4184–87–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

Tribal Consultation Meeting

AGENCY: Office of Head Start (OHS), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS).

ACTION: Notice of meeting.

SUMMARY: Pursuant to the Head Start Act, notice is hereby given of one Tribal Consultation session to be held between HHS/ACF OHS leadership and the leadership of Tribal governments operating Head Start and Early Head Start programs. The purpose of this consultation session is to discuss ways to better meet the needs of American Indian and Alaska Native (AIAN) children and their families, taking into consideration funding allocations, distribution formulas, and other issues affecting the delivery of Head Start services in their geographic locations.

DATES: Wednesday, September 16, 2026—1:00–4:00 p.m. ET.

ADDRESSES: Virtual: Registration information for the virtual event will be forthcoming.

FOR FURTHER INFORMATION CONTACT: Office of Head Start, email *AIANHeadStart@acf.hhs.gov.* Additional information and online meeting registration will be forthcoming.

SUPPLEMENTARY INFORMATION: In accordance with section 640(l)(4) of the Head Start Act, 42 U.S.C. 9835(1)(4), ACF announces OHS Tribal Consultation session for leaders of Tribal governments operating Head Start and Early Head Start programs.

The agenda for the scheduled OHS Tribal Consultation reflects the statutory purposes of Head Start Tribal Consultations related to meeting the needs of AIAN children and families. OHS will also highlight the progress made in addressing issues and concerns

raised in the previous OHS Tribal Consultations.

The consultation session includes elected or appointed Leaders of Tribal governments and their designated representatives. Designees must have a letter from the Tribal government authorizing them to represent the Tribe. Tribal governments must submit the designee letter at least 3 days before the consultation session to the Office of Head Start at *AIANHeadStart@acf.hhs.gov.* Other representatives of Tribal organizations and Native nonprofit organizations are welcome to attend as observers.

Within 45 days of the consultation process, a detailed report of the consultation session will be available for all Tribal governments receiving funds for Head Start and Early Head Start programs. Tribes can submit written testimony for the report to the Office of Head Start at *AIANHeadStart@acf.hhs.gov* prior to the consultation session or by October 6, 2026. OHS will summarize oral testimony and comments from the consultation session in the report, along with topics of concern and recommendations.

Roshelle M. Brooks,

Management Analyst and OFR Liaison.

[FR Doc. 2026–16826 Filed 8–17–26; 8:45 am]

BILLING CODE 4184–40–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2026–N–5479]

Testosterone Use in Menopausal Women; Public Workshop; Request for Comments

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of public workshop.

SUMMARY: The Food and Drug Administration's (FDA) Office of Women's Health and the Center for Drug Evaluation and Research are announcing a public workshop titled ''Testosterone Use in Menopausal Women.'' The purpose of the public workshop is to examine the current scientific evidence and critical knowledge gaps related to testosterone use in menopausal women to help inform future research and potential drug development of testosterone products for menopausal women. Researchers, educators, industry, clinicians, patients, and consumers may benefit from attending this scientific workshop. Presentations will examine the physiological roles of testosterone throughout a woman's life, including age-related decline, the menopausal transition, challenges associated with measuring and interpreting testosterone blood levels, and how these levels correlate with clinical symptoms and conditions. Speakers will review current and potential clinical uses of testosterone in menopausal women and examine the strengths and limitations of available data supporting those uses. Speakers will discuss regulatory considerations, including the development of robust efficacy and safety data, to support a marketing application for testosterone in menopausal women for the treatment of various clinical conditions, and study design considerations for evaluating long-term safety outcomes in women.

DATES: The public workshop will be held on September 17, 2026, from 9:00 a.m. to 4:30 p.m. Eastern Time. See the **SUPPLEMENTARY INFORMATION** section for registration date and information.

ADDRESSES: The public workshop will be held as a hybrid event via webcast and an in-person option at the FDA White Oak Campus, Great Room, Bldg. 31, 10903 New Hampshire Ave., Silver Spring, MD 20993. Entrance for the public workshop participants (non-FDA employees) is through Building 1 where routine security check procedures will be performed. For parking and security information, please refer to *https://www.fda.gov/about-fda/visitor-information/public-meeting-information* and *https://www.fda.gov/about-fda/visitor-information/visitor-parking-and-campus-map.*

You may submit comments, data, and information as follows. Please note that late, untimely filed comments will not be considered. The *https://www.regulations.gov* electronic filing system will accept comments until 11:59 p.m. Eastern Time at the end of October 19, 2026. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are received on or before that date.

Electronic Submissions

Submit electronic comments in the following way:

- *Federal eRulemaking Portal: https://www.regulations.gov.* Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to *https://www.regulations.gov* will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on *https://www.regulations.gov.*
- If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the manner detailed (see ''Written/Paper Submissions'' and ''Instructions'').

Written/Paper Submissions

Submit written/paper submissions as follows:

- *Mail/Hand Delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ''Instructions.''

Instructions: All submissions received must include Docket No. FDA–2026–N–5479 for ''Testosterone Use in Menopausal Women; Public Workshop; Request for Comments.'' Received comments, those filed in a timely manner (see **ADDRESSES**), will be placed in the docket and, except for those submitted as ''Confidential Submissions,'' publicly viewable at *https://www.regulations.gov* or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240–402–7500.

Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ''THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on *https://www.regulations.gov.* Submit both copies to the Dockets Management Staff. If you do not wish your name and